| Autor: |
Mohamed Ahmed, Matthew Lee, Ahmed Mahmoud, Vidhu Joshi, Ajay Gopalakrishna, Raevti Bole, Rimki Haloi, Ayse Kendi, Michael Bold, Alan Bryce, R Jeffrey Karnes, Eugene Kwon, Daniel Childs, Jack Andrews |
| Rok vydání: |
2023 |
| Popis: |
Background The objective of this study was to evaluate the prognostic value of early PSA decline following initiation of second-generation hormone therapy (2nd HT), namely abiraterone acetate or enzalutamide, in patients with taxane-refractory metastatic castrate-resistant prostate cancer (mCRPC) and evaluate utility of this metric in informing intensified surveillance/imaging protocols. Methods We retrospectively identified 75 mCRPC patients treated with 2nd HT following docetaxel failure (defined as PSA rise and radiographic progression). Patients were categorized patients into two cohorts based on the first PSA within 3 months after initiation of therapy: PSA reduction ≥ 50% (Group A) and PSA reduction |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
